The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Monoclonal antibody therapy of cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tai, Y., Catley, L. P., Mitsiades, C. S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3630 · Cited by 130
RetractedRadioimmunotherapy of small-volume disease of metastatic colorectal cancer
Behr, T. M., Liersch, T., Greiner‐Bechert, L., Griesinger, F., Béhé, M. P., Markus, P. M., Gratz, S., Angerstein, C., Brittinger, G., Heinz Becker, A., et al. (2002) · Cancer · doi:10.1002/cncr.10308 · Cited by 110
RetractedContinuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Gold, P., & Freedman, S. O. (1965) · The Journal of Experimental Medicine · doi:10.1084/jem.121.3.439 · Cited by 2,310
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Self-citationComplement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRn
Ghetie, V., & Ward, E. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.739 · Cited by 474
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Sheets, M. D., Amersdorfer, P., Finnern, R., Sargent, P., Lindqvist, E., Schier, R., Hemingsen, G., Wong, C., Gerhart, J. C., & Marks, J. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6157 · Cited by 438
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Radioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Mendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X.-C., Maynard-Currie, C. E., Yang, X.-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376
Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369
Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368
Burstein, H. J., Kuter, I., Campos, S. M., Gelman, R. S., Tribou, L., Parker, L. M., Manola, J., Younger, J., Matulonis, U., Bunnell, C. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2722 · Cited by 366
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M., Dodd, S. W., Wood, J. F., Whitlow, M. D., Snoy, P. J., & Schlom, J. (1991) · PubMed · Cited by 338
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., et al. (2003) · PubMed · Cited by 335
Gribben, J., Freedman, A., Woo, S., Blake, K., Shu, R., Freeman, G., Longtine, J., Pinkus, G., & Nadler, L. (1991) · Blood · doi:10.1182/blood.v78.12.3275.3275 · Cited by 330
Hu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
Yang, X., Jia, X., Corvalan, J. R. F., Wang, P., Davis, C., & Jakobovits, A. (1999) · PubMed · Cited by 328
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 303
ARTEAGA, C. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70085-7 · Cited by 302
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Byrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
Vanhoefer, U., Tewes, M., Rojo, F., Dirsch, O., Schleucher, N., Rosen, O., Tillner, J., Kovar, A., Braun, A. H., Trarbach, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.114 · Cited by 261
Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3257 · Cited by 255
Reardon, D. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1389 · Cited by 255
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Ely, S., Furman, R. R., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.082 · Cited by 253
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Messa, C., Russo, F., Gabriella Caruso, M., & Di Leo, A. (1998) · Acta Oncologica · doi:10.1080/028418698429595 · Cited by 251
Adams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., & Weiner, L. M. (1993) · PubMed · Cited by 248
Self-citationFan, Z., Masui, H., Altas, I., & Mendelsohn, J. M. (1993) · PubMed · Cited by 245
Herbst, R. S., & Langer, C. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31525 · Cited by 237
Design and production of novel tetravalent bispecific antibodies
Coloma, M. J., & Morrison, S. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-159 · Cited by 236
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Self-citationArteaga, C. L. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35642 · Cited by 228
Clinical trials of Herceptin® (trastuzumab)
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00404-4 · Cited by 227
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Furman, R., Schuster, M. W., Feldman, E. J., Ashe, M., Schuster, S. J., Wegener, W. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0294 · Cited by 226
van Mierlo, G. J. D., den Boer, A. T., Medema, J. P., van der Voort, E. I. H., Fransen, M. F., Offringa, R., Melief, C. J. M., & Toes, R. E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082107699 · Cited by 222
Sundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., & Wu, A. M. (2003) · PubMed · Cited by 222
Foon, K. A., Yang, X.-D., Weiner, L. M., Belldegrun, A. S., Figlin, R. A., Crawford, J., Rowinsky, E. K., Dutcher, J. P., Vogelzang, N. J., Gollub, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.098 · Cited by 218
Self-citationNatural and designer binding sites made by phage display technology
Hoogenboom, H. R., & Chames, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01667-4 · Cited by 213
Adams, G., Schier, R., McCall, A., Crawford, R., Wolf, E., Weiner, L., & Marks, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.233 · Cited by 208
Self-citationHale, G., Zhang, M.-J., Bunjes, D., Prentice, H. G., Spence, D., Horowitz, M. M., Barrett, A. J., & Waldmann, H. (1998) · Blood · doi:10.1182/blood.v92.12.4581 · Cited by 194
Monoclonal Antibody Therapy for Cancer
Mehren, M. V., Adams, G. P., & Weiner, L. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152442 · Cited by 191
Self-citationLeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F. M., Platanias, L. C., Schwartz, G. N., Ratain, M. J., Rook, A. H., Freytes, C. O., Craig, F. E., et al. (1998) · PubMed · doi:10.1182/blood.v91.2.399 · Cited by 184
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V, Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Cheng, C. L., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali-Osman, F., Szabo, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600517 · Cited by 163
Zhu, Z., Hattori, K., Zhang, H., Jimenez, X., Ludwig, D. L., Dias, S., Kussie, P., Koo, H., Kim, H. J., Lu, D., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402831 · Cited by 158
Kreitman, R. J., & Pastan, I. H. (1995) · Biochemical Journal · doi:10.1042/bj3070029 · Cited by 154
Johns, T. G., Adams, T. E., Cochran, J. R., Hall, N. E., Hoyne, P. A., Olsen, M. J., Kim, Y., Rothacker, J., Nice, E. C., Walker, F., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401218200 · Cited by 150
Arteaga, C. L., Coronado, E. B., & Osborne, C. K. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-11-1064 · Cited by 136
Bowen, A., Zomas, A., Emmett, E., Matutes, E., Dyer, M. J. S., & Catovsky, D. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2061.x · Cited by 129
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
Cheng, J. D., Valianou, M., Canutescu, A. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0269 · Cited by 129
Scott, A. M., Lee, F.-T., Jones, R., Hopkins, W., MacGregor, D. P., Cebon, J. S., Hannah, A., Chong, G., Paul, U., Papenfuss, A. T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2329 · Cited by 126
Gordon, L. I., Witzig, T. E., Molina, A., Czuczman, M. S., Emmanouilides, C. E., Joyce, R., Vo, K., Theuer, C. P., Pohlman, B. L., Bartlett, N. L., et al. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.n.015 · Cited by 124
May, K. F., Chen, L., Zheng, P., & Liu, Y. (2002) · PubMed · Cited by 122
Vuist, W. M. J., Levy, R., & Maloney, D. G. (1994) · Blood · doi:10.1182/blood.v83.4.899.899 · Cited by 110
Pavlínková, G., Beresford, G., Booth, B. J. M., Batra, S. K., & Colcher, D. M. (1999) · PubMed · Cited by 107
Heijnen, I., & van de Winkel, J. G. J. (1997) · International Reviews of Immunology · doi:10.3109/08830189709045702 · Cited by 103
James, N. D., Atherton, P. J., Jones, J. L., Howie, A. J., Tchekmedyian, S., & Curnow, R. T. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1878 · Cited by 100
The epidermal growth factor receptor as a target for colorectal cancer therapy
Lockhart, C., & Berlin, J. D. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.09.036 · Cited by 97
Wong, J. Y. C., Chu, D. Z. J., Yamauchi, D. M., Williams, L. E., Liu, A., Wilczynski, S. P., Wu, A. M., Shively, J. E., Doroshow, J. H., & Raubitschek, A. A. (2000) · PubMed · Cited by 85
Mayer, A., Sharma, S. K., Tolner, B., Minton, N. P., Purdy, D., Amlot, P. L., Tharakan, G., Beǵent, R. H. J., & Chester, K. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601888 · Cited by 84
Lin, M. I., & Sessa, W. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.003 · Cited by 81
Mayer, A., Tsiompanou, E., O'Malley, D., Boxer, G., Bhatia, J., Flynn, A. A., Chester, K. A., Davidson, B. R., Lewis, A. A. M., Winslet, M. C., et al. (2000) · PubMed · Cited by 75
Leonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74
Anaphylactic Shock after Retreatment with OKT3 Monoclonal Antibody
Abramowicz, D., Crusiaux, A., & Goldman, M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271018 · Cited by 71
Juweid, M., Hajjar, G., Stein, R., Sharkey, R. M., Herskovic, T., Swayne, L. C., Suleiman, S., Pereira, M. A., Rubin, A., & Goldenberg, D. M. (2000) · PubMed · Cited by 71
Hoffmann, T. K., Häfner, D., Balló, H., et al. (1998) · PubMed · Cited by 68
Hartung, G., Hofheinz, R. D., Dencausse, Y., et al. (2005) · Oncology Research and Treatment · doi:10.1159/000084595 · Cited by 64
Rituximab in the treatment of diffuse large B-cell lymphomas
Coiffier, B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30153 · Cited by 63
Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIII
Weiner, L. M., Clark, J. I., Ring, D. B., & Alpaugh, R. K. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.453 · Cited by 57
Self-citationBajorin, D. F., Chapman, P. B., Wong, G. Y., Cody, B. V., Cordon‐Cardo, C., Dantes, L., Templeton, M. A., Scheinberg, D., Oettgen, H. F., & Houghton, A. N. (1992) · Melanoma Research · doi:10.1097/00008390-199212000-00009 · Cited by 49
Sunada, H., Yu, P., Peacock, J. S., & Mendelsohn, J. M. (1990) · Journal of Cellular Physiology · doi:10.1002/jcp.1041420210 · Cited by 47
Rizzieri, D. A., Akabani, G., Zalutsky, M. R., Coleman, R. E., Metzler, S. D., Bowsher, J. E., Toaso, B., Anderson, E. L., Lagoo, A. S., Clayton, S., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4264 · Cited by 47
Lee, J. J., Fenton, B. M., Koch, C. J., Frelinger, J. G., & Lord, E. M. (1998) · PubMed · Cited by 43
Funakoshi, S., Longo, D. L., & Murphy, W. J. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199603000-00002 · Cited by 41
Modjtahedi, H., Komurasaki, T., Toyoda, H., & Dean, C. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980119)75:2<310::aid-ijc22>3.0.co;2-f · Cited by 29
Lewis, L. D., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Guyre, P. M., Fanger, M. W., Curnow, R. T., Kaufman, P. A., & Ernstoff, M. S. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00355-0 · Cited by 26
Shankar, S., Vaidyanathan, G., Affleck, D. J., Peixoto, K. V., Bigner, D. D., & Zalutsky, M. R. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.04.007 · Cited by 22
Cited by
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Metadata
- Authors
- Adams, G. P., & Weiner, L. M.
- Venue
- Nature Biotechnology
- Published
- 2005-09
- Volume
- 23
- Issue
- 9
- Pages
- 1147-1157
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2083982805
- Cited by
- 1,246
- References
- 141
- FWCI
- 60.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.